Cure8 trial brief
The study will test whether routine point‑of‑care intestinal ultrasound changes clinical decisions compared with standard monitoring, which could make monitoring less invasive and more responsive if effective.
Adult patients with Crohn’s disease or ulcerative colitis, IBD clinicians, and researchers focused on monitoring and management strategies.
This is a single-center, interventional randomized trial (recruiting) at Mahidol University in Bangkok. Adults with IBD undergoing endoscopy are randomized 1:1 to standard of care plus IUS at every visit versus standard care alone and followed for 48 weeks.
IUS exams assess bowel wall thickness, color Doppler signal, and mesenteric fat and are performed by IBUS‑certified physicians who are blinded to same‑day blood and stool test results. Standard of care in both arms includes clinical scores (partial Mayo or HBI/PRO‑2), CBC, CRP, fecal calprotectin, and colonoscopy as indicated.
The primary outcome is the proportion of participants with a change in treatment (medication changes, surgery, or hospitalization) during follow-up.
This is a registered, recruiting interventional trial and does not provide results. Eligibility and single‑center conduct may limit how widely the findings apply.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD who have no or few symptoms but still have moderate–severe inflammation on endoscopy face uncertainty about whether to switch therapies to aim for endoscopic remission.
IBD patients can have lung involvement without symptoms. Simple spirometry focused on small-airway measures might help detect early pulmonary changes and prompt further evaluation or monitoring.
The study tests whether adding MRI-based transmural assessment to a fecal-calprotectin–guided (CALM) strategy improves the ability to keep people with Crohn’s disease in corticosteroid-free clinical remission and may...
